Table 1 Patient characteristics
Patient charactiristics(n = 8) | NO. (%) | All patient (%) |
|---|---|---|
PRS.type | ||
Primary | 6(75%) | 8(100%) |
secondary | 2(25%) | 8(100%) |
History | ||
GBM | 8(100%) | 8(100%) |
Grade | ||
WHO IV | 8(100%) | 8(100%) |
Gender | ||
male | 4(50%) | 8(100%) |
Female | 4(50%) | 8(100%) |
Age | ||
40–50 | 2(25%) | 8(100%) |
50–60 | 3(37.5%) | 8(100%) |
≥ 60 | 3(37.5%) | 8(100%) |
PD-L1 | ||
<1% | 7(87.5%) | 8(100%) |
≥ 1% | 1(12.5%) | 8(100%) |
Ki−67 | ||
0–20 | 2(28.6%) | 7(87.5%) |
≥ 20 | 5(71.4%) | 7(87.5%) |
P53 | ||
wildtype | 4(57.1%) | 7(87.5%) |
Mutant | 3(42.9%) | 7(87.5%) |
IDH−1 | ||
wildtype | 7(100%) | 7(87.5%) |
Mutant | 0 | 7(87.5%) |
MGMTp.methylation.status | ||
Methylated | 1(14.3%) | 7(87.5%) |
Unmethylated | 6(85.7%) | 7(87.5%) |
1p.19q.codeletion.status | ||
Non-codel | 2(100%) | 2(25%) |
codel | 0 | 2(25%) |
No. of recurrences | ||
1 | 3(37.5%) | 8(100%) |
2 | 5(62.5%) | 8(100%) |
prior therapy | ||
Surgery | 1(20%) | 5(62.5%) |
Chemotherapy | 4(80%) | 5(62.5%) |
Radiation | 0 | 4(50%) |
Corticosteroid use at baseline | ||
Yes | 2(25%) | 8(100%) |
No | 6(75%) | 8(100%) |
Treatment-related AEs | ||
all grade | 3(37.5%) | 8(100%) |
Grade 3 treatment-related AEs | 1(33.3%) | 8(100%) |
Grade 1–2 treatment-related AEs | 3(37.5%) | 8(100%) |